Emmaus Life Sciences (EMMA) presents a deeply negative liquidation posture at December 31, 2025. MFFAIS-reported CLV of negative $68.4M, LLV of negative $65.6M, and OLV of negative $64.0M are consistent with the balance sheet: total assets of $21.4M against total liabilities of $85.0M, yielding book equity of negative $63.6M. Under liquidation haircuts, the asset side deteriorates further. Cash of $2.1M recovers at par. Accounts receivable of $2.8M recovers at approximately $2.5-2.7M. Inventory carries gross of $11.8M but a $5.1M reserve reduces net to $1.6M; applying a 60% recovery to net inventory yields approximately $0.9M. PP&E net of $0.1M recovers perhaps $0.05-0.1M. The Telcon convertible bond ($12.6M fair value, Level 3) is the largest single asset but receives a steep haircut under liquidation—it is an illiquid KRW-denominated private instrument maturing 2030 bearing only 2.1% interest; fire-sale recovery is indeterminate but likely well below book. ROU asset ($0.8M) has minimal recovery. Total recoverable assets under liquidation are likely $18-20M before the Telcon bond uncertainty. Against liabilities at face: current liabilities of $69.1M include $17.4M convertible notes, $17.6M in other current liabilities, $5.8M accrued interest, $9.3M accrued liabilities, and $6.0M accounts payable. Non-current liabilities of $15.9M include $12.3M other non-current and $1.4M operating lease. Total debt principal per the filing is $30.8M gross carrying amount with $0.24M unamortized discount. Total liability face value of $85M dwarfs any plausible asset recovery. The accumulated deficit reached $270.1M. Compared to the prior 10-Q (period end September 30, 2025), the annual filing shows total debt increased (DebtInstrumentCarryingAmount $30.8M vs. prior period disclosures of $15.9M convertible plus $10.9M other notes = $26.8M), interest expense of $7.1M for the full year, and a $1.4M debt extinguishment loss. Post-period, a February 2026 Sale of Future Receipts Agreement sold $1.7M of receivables for $1.1M net—a 35% effective cost implying severe liquidity stress. The NIT license arrangement (Endari U.S. rights, Effective Date contingent on NIT regulatory approval by October 1, 2026) introduces a potential structural change to revenue but does not affect the current liquidation balance sheet. The Telcon API supply agreement carries an annual purchase target shortfall risk that has already resulted in offset against the convertible bond principal. Going concern doubt is explicitly noted. The filing discusses an accumulated deficit, going concern qualification, and API purchase shortfalls in MD&A but the specific shortfall offset amounts are disclosed narratively rather than in a dedicated XBRL tag.
▼ Community Notes